NCT03011892

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream-Controlled Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 307 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to establish the efficacy of each strength of ruxolitinib cream once daily (QD) or twice daily (BID) in participants with atopic dermatitis as compared with vehicle cream BID.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	Ruxolitinib 0.15% Cream QD	Ruxolitinib 0.15% cream QD
DRUG	Ruxolitinib 0.5% Cream QD	Ruxolitinib 0.5% cream QD
DRUG	Ruxolitinib 1.5% Cream QD	Ruxolitinib 1.5% cream QD
DRUG	Ruxolitinib 1.5% Cream BID	Ruxolitinib 1.5% cream BID
DRUG	Triamcinolone 0.1% Cream BID	Triamcinolone 0.1% cream BID
DRUG	Vehicle Cream BID	Vehicle cream BID

Timeline

• Start date: 2017-01-09
• Primary completion: 2018-01-10
• Completion: 2018-03-12
• First posted: 2017-01-05
• Last updated: 2021-04-09
• Results posted: 2021-04-09

Locations

52 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study